W-0101 (Pierre Fabre Medicament) |
W-0101 |
Phase Ⅱ |
Pierre Fabre |
Solid tumours |
Details
|
VF-001 |
VF-001; VF-001-DP-HD; VF-001-DP-LD,VF 001; VF 001 DP HD; VF 001 DP LD,VF001; VF001 DPHD; VF001DPLD |
Phase Ⅱ |
Factor Therapeutics |
Leg ulcer |
Details
|
AMT-070 |
AMT-070 |
Preclinical |
Digna Biotech, Amsterdam Molecular Therapeutics |
Liver cirrhosis |
Details
|
Insulin-Like Growth Factor 1 (Wright State Physicians) |
|
Phase Ⅰ |
Wright State Physicians |
Sunburn, Skin aging |
Details
|
Ganitumab |
AMG-479 |
Phase Ⅲ |
Amgen, Millennium Pharmaceutical, National Cancer Institute |
Solid tumours, Ewing's Sarcoma |
Details
|
Cixutumumab |
A-12; IMC-A12; LY-3012217; NSC-742460 |
Phase Ⅱ |
Lilly, National Cancer Institute |
Breast cancer, Solid tumours, Soft tissue sarcoma, Sarcoma, Hepatocellular carcinoma (HCC), Head and neck cancer, Rhabdomyosarcoma, Thymic tumor, Neuroendocrine tumors (NET), Non small cell lung cancer (NSCLC), Prostate cancer, Esophageal adenocarcinoma, Colorectal cancer, Pancreatic cancer |
Details
|
Pegylated insulin-like growth factor 1 |
RG-7010; IGF1-PEG |
Phase Ⅰ |
Roche |
Amyotrophic lateral sclerosis (ALS) |
Details
|
XL-228 |
XL-228 |
Phase Ⅰ |
Exelixis |
Solid tumours, Acute lymphoblastic leukaemia (ALL), Chronic myeloid leukemia (CML ) |
Details
|
VPI-2690B |
VPI-2690B |
Phase Ⅱ |
University of North Carolina, Vascular Pharmaceuticals |
Diabetic nephropathy |
Details
|
KW-2450 |
KW-2450 |
Phase Ⅱ |
Kyowa Hakko Kirin |
Breast cancer |
Details
|
PL-2258 |
PL-2258; PL2258-Merck; PL-2258B |
Phase Ⅰ |
Merck Sharp & Dohme, Piramal Phytocare |
Solid tumours |
Details
|
INSM-18 |
INSM-18; INS-18; TT-100,INSM18 |
Phase Ⅱ |
Insmed, University of California |
Prostate cancer |
Details
|
ATL-1101 |
ATL-1101 |
Phase Ⅰ |
Antisense Therapeutics |
Psoriasis |
Details
|
Anti-IGF-1R monoclonal antibody (Genentech) |
rhuMAb-IGFR |
Phase Ⅰ |
Genentech |
Solid tumours |
Details
|
Conteltinib |
CT-707; SY-707 |
Phase Ⅲ |
Shouyao Holdings, Centaurus Biopharma |
Anaplastic lymphoma kinase (ALK)-positive NSCLC |
Details
|
BMS-754807 |
BMS-754807,BMS754807 |
Phase Ⅱ |
Bristol-Myers Squibb |
Breast cancer |
Details
|
Linsitinib |
ASP-7487; OSI-906; OSI-906AA,ASP7487,OSI906,OSI906AA |
Phase Ⅲ |
Astellas, National Cancer Institute |
Adrenocortical carcinoma |
Details
|
Mecasermin (Chiron/SkyePharma) |
|
Phase Ⅱ |
Chiron, SkyePharma |
Osteoarthritis (OA) |
Details
|
CT102 |
CT-102 |
Phase Ⅰ |
Institute of Pharmacology & Radiation of AMMS, Hangzhou Tianlong Pharmaceuticals |
Hepatocellular carcinoma (HCC) |
Details
|
124I-CPD-1023-figitumumab |
FPX-1028; CPD-1028-[125I]; CPD-1028-[124I]; 125I-CPD-1028; 124I-CPD-1028 |
Phase Ⅰ |
Fusion Pharma |
Cancer |
Details
|
Picropodophyllin |
AXL-1717; NSC-36407; PPP,AXL1717 |
Phase Ⅱ |
Axelar |
Non small cell lung cancer (NSCLC), Astrocytoma |
Details
|
IGV-001 |
IGV-001 |
Phase Ⅰ |
Imvax |
Glioblastoma |
Details
|
AVE-1642 |
AVE-1642 |
Phase Ⅱ |
ImmunoGen, Sanofi |
Breast cancer, Solid tumours, Multiple myeloma (MM) |
Details
|
Figitumumab |
CP-751871 |
Phase Ⅲ |
Pfizer |
Small cell lung cancer (SCLC), Non small cell lung cancer (NSCLC), Breast cancer, Multiple myeloma (MM), Ewing's Sarcoma, Head and neck cancer, Cancer |
Details
|
Rinfabate |
|
Phase Ⅰ |
Insmed |
Solid tumours |
Details
|
Dalotuzumab |
MK-0646; F-50-035; h7C-10 |
Phase Ⅱ |
Pierre Fabre, Merck Sharp & Dohme |
Breast cancer, Colorectal cancer |
Details
|
PL-225B |
PL-225B,PL225B |
Phase Ⅰ |
Piramal Phytocare |
Solid tumours |
Details
|
FPX-01 (Fusion Pharmaceuticals) |
FPX-01;[225Ac]-FPI-1434 |
Phase Ⅰ |
Fusion Pharma |
Solid tumours |
Details
|
Istiratumab |
MM-141; XLR461MD3M (UNII code) |
Phase Ⅱ |
Merrimack, Shire, Adimab |
Ovarian cancer, Pancreatic cancer |
Details
|
IGF-1 receptor oligodeoxynucleotide-based immunotherapy (Thomas Jefferson University) |
|
Phase Ⅰ |
Sidney Kimmel Cancer Center |
Glioma |
Details
|
BIIB-022 |
BIIB-022 |
Phase Ⅰ |
Biogen |
Non small cell lung cancer (NSCLC), Solid tumours, Hepatocellular carcinoma (HCC) |
Details
|
Robatumumab |
19-D12; SCH-717454; SCHOOL-717454,19D12 |
Phase Ⅱ |
Merck Sharp & Dohme |
Solid tumours, Colorectal cancer, Sarcoma, Osteosarcoma |
Details
|